Summary: JAK mutations could be one of the primary escape mechanisms to anti–PD-1/PD-L1 immunotherapy via impaired IFNγ signaling in cancer cells and could be used
A genetically manipulated version of the gastroenteritis-causing bacteria Salmonella typhimurium is a potent destroyer of mouse tumors, according to a report published today (February 8)
Contemporary immunotherapies (e.g., immune checkpoint inhibitors), which enhance the immune response to cancer cells, improve clinical outcomes in several malignancies. A recent study reported the
The TNF (tumor necrosis factor) ligand family promotes tumor growth and progression. Torrey et al. developed an antibody that locks TNFR2, a TNF receptor found
Cancer is notorious for relapsing after treatment. Such relapses are driven by tumor-initiating cells, a type of stem cell that gives rise to tumors. Damelin
For more than half a century, the treatment of cancer has relied heavily on radiation, surgery, chemotherapy and, increasingly, the use of drugs that target
After decades of frustration, efforts to develop antibodies that can ferry drugs into cancer cells — and minimize damage to healthy tissue — are gathering
Antibodies that block CTLA-4 (cytotoxic T lymphocyte–associated antigen 4) and PD-1 (programmed death 1) allow T cells to launch antitumor immune responses. Although these checkpoint
Roche said today it will launch a CHF 100 million ($100.1 million) global network of 21 academic centers focused on cancer immunotherapy R&D. The new
Roche said today it will launch a CHF 100 million ($100.1 million) global network of 21 academic centers focused on cancer immunotherapy R&D. The new
If combination immunotherapies show promise against established tumors, why not try super-combo immunotherapies? That’s the question that occurred to MIT scientists, who had achieved partial
Adoptive cell therapy (ACT) has shown promise for a variety of cancer subtypes, with clinical trial data showing that up to 40% of Stage IV
Highlights •The interaction between HVEM and BTLA is lost in most follicular lymphomas •Loss of HVEM activates B cells and induces a supportive microenvironment •Soluble
Amyloid-β proteins form plaques in the brain that are a hallmark of Alzheimer’s disease. Designed to clear these plaques, the antibody aducanumab is demonstrating early
Oncologist You Lu of Sichuan University’s West China Hospital in Chengdu and colleagues will soon begin trialing a new CRISPR-based immunotherapy in 10 patients with
Single-agent immunotherapy has achieved limited clinical benefit to date in patients with pancreatic ductal adenocarcinoma (PDAC). This may be a result of the presence of
Following the deaths of three patients in a phase II cancer immunotherapy clinical trial, Juno Therapeutics has put the brakes on the study. The firm
Cancer research is a rapidly evolving field with new discoveries emerging daily on its biology, prevention, diagnosis, and treatment. In particular, the recent achievement of several
Myc, a transcriptional regulator that is overexpressed in several human cancers, appears to have a direct role in preventing immune cells from efficiently attacking tumor
Scientists from KU Leuven in Belgium say they have shown that next-generation cell-based immunotherapy may offer new hope in the fight against brain cancer. Cell-based
A coalition of pharma and biotech giants, major academic cancer centers, and community oncologists have joined with Independence Blue Cross and Bank of America to
Merck & Co. said this afternoon it has acquired IOmet Pharma, a small-molecule drug developer focused on cancer immunotherapy and cancer metabolism, for an undisclosed
Merck & Co. said this afternoon it has acquired IOmet Pharma, a small-molecule drug developer focused on cancer immunotherapy and cancer metabolism, for an undisclosed
Gut microbes have ascended to prominence as key modulators of host immunity, raising the possibility that they could influence the outcome of cancer immunotherapy. Two
A London baby with end-stage leukemia has received a remarkable new cancer treatment: off-the shelf T cells with several gene modifications. Doctors say it’s too
Created by ePubSystems. Contact Us for similar site for your university or institute.